Table S2.

Example of a dominant fixed choice task. Two dominant fixed choice tasks without an “opt-out” or “no-treatment” option were included in the discrete choice experiment.

DMARD characteristic	Medicine 1	Medicine 2
Route of administration	Oral (tablets/capsules)	Oral (tablets/capsules)
Frequency of administration	Weekly	Weekly
Onset of action	12 weeks	Six weeks
Risk of cancer (eg, skin cancer with favorable prognostic factors)	1 of 1,000 patients (0.1%)	No risk
Risk of liver injury (eg, elevated levels of liver damage markers)	1 of 1,000 patients (0.1%)	No risk
Risk of serious infections (eg, hospital admissions/discontinuation of anti-rheumatic drugs)	1 of 100 patients (1.0%)	No risk
Chance of efficacy	60%	80%
Preference for Medicine 1 or Medicine 2	□	□

Abbreviation: DMARD, disease-modifying antirheumatic drug.